Skip to content

Beam Therapeutics Inc

BEAM

Latest QuantConomy context for BEAM: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class
stock
Primary venue
NASDAQ
Recent signals
3
SEC filings
20
Asset profile

Beam Therapeutics Inc

QuantConomy has a structured record for BEAM. More descriptive asset metadata will appear here when the platform record includes it.

Symbol
BEAM
Name
Beam Therapeutics Inc
Coverage
3 market/data records
Sources
fmp alpaca alphavantage sec nasdaq binance
Latest signal rows

Recent signals for BEAM

Scored rows are pulled from the same signal API used by the digests.

Signal Direction Score Observed Reason
large sale
bearish
45
Jun 29, 06:36 PM FMR LLC (10% Owner) sold BEAM shares ($1.17M) - 33,372 shares - [weak bearish signal]
earnings release
neutral
40
Jan 12, 12:00 AM BEAM filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-01-12. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read).
earnings release
neutral
40
Feb 24, 12:00 AM BEAM filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-02-24. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read).

EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).

PRICE signals are experimental: realized 30-day directional accuracy is ~18% (short-horizon price moves tend to mean-revert). They are automatically down-weighted in composite scores but served raw here. Do not use them as standalone trade advice.

Market coverage

Market Exchange Source Asset record
BEAM NASDAQ fmp Beam Therapeutics Inc.
BEAM NASDAQ alpaca Beam Therapeutics Inc. Common Stock
BEAM NASDAQ alphavantage Beam Therapeutics Inc

Recent insider transactions

Buys, last 90d
0
Sells, last 90d
1
Rows
20
Date Insider Role Type Shares Price Value Filing
Jun 29, 2026 Evans John M. CEO exercise 18,663 $0.67 $12,504 4 on EDGAR
Jun 25, 2026 FMR LLC 10% owner sale 33,372 $35.12 $1,172,025 4 on EDGAR
Jun 17, 2026 Ciaramella Giuseppe President exercise 6,505 $0.67 $4,358 4 on EDGAR
Jun 3, 2026 Walsh Kathleen E Director grant 19,676 4 on EDGAR
Jun 3, 2026 Guindo Chirfi Director grant 19,676 4 on EDGAR
Jun 3, 2026 Fishman Mark Director grant 19,676 4 on EDGAR
Jun 3, 2026 MARAGANORE JOHN Director grant 19,676 4 on EDGAR
Jun 3, 2026 Shaw Christi Director grant 19,676 4 on EDGAR
Jun 3, 2026 COOPER GRAHAM K Director grant 19,676 4 on EDGAR
Apr 1, 2026 Evans John M. CEO sale 30,078 $24.58 $739,317 4 on EDGAR
Apr 1, 2026 Bellon Christine Chief Legal Officer sale 5,956 $24.58 $146,398 4 on EDGAR
Apr 1, 2026 Ciaramella Giuseppe President sale 11,810 $24.58 $290,290 4 on EDGAR
Apr 1, 2026 Simon Amy Chief Medical Officer sale 6,700 $24.58 $164,686 4 on EDGAR
Apr 1, 2026 Cavanagh Bethany J SVP, Finance and Treasurer sale 3,242 $24.58 $79,688 4 on EDGAR
Mar 31, 2026 Cavanagh Bethany J SVP, Finance and Treasurer grant 20,000 $0.00 $0 4 on EDGAR
Mar 31, 2026 Ciaramella Giuseppe President grant 40,000 $0.00 $0 4 on EDGAR
Mar 31, 2026 Bellon Christine Chief Legal Officer grant 20,000 $0.00 $0 4 on EDGAR
Mar 31, 2026 Simon Amy Chief Medical Officer grant 31,750 $0.00 $0 4 on EDGAR
Mar 31, 2026 Emany Sravan Kumar Chief Financial Officer grant 31,750 $0.00 $0 4 on EDGAR
Mar 30, 2026 Evans John M. CEO exercise 25,000 $0.67 $16,750 4 on EDGAR

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

Query BEAM context like a database.

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.

No spam, no noise. Just the launch and the occasional preview.

More: All insider trades · How to read a Form 4 · API access